Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis

Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis

The "Hepatology Digest - Liver Vascular Diseases" column is a scholarly column co-initiated by Dr. Xingshun Qi from the Department of Gastroenterology at the General Hospital of Northern Theater Command, at the invitation of the editorial board of Hepatology Digest. This column regularly collects and summarizes research progress in the field of liver vascular diseases, selecting and discussing one significant paper every two weeks (Wednesday). The aim is to help readers understand the reasoning behind the findings, inspire clinical research thinking, and apply what they have learned in practice.
Hepatol Int | 24-Hour Comprehensive Lifestyle Interventions Help Prevent and Control MAFLD

Hepatol Int | 24-Hour Comprehensive Lifestyle Interventions Help Prevent and Control MAFLD

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide, with recent data showing prevalence rates of up to 39% in adults and 20% in children. MAFLD is characterized by overweight or obesity, type 2 diabetes, and/or metabolically dysregulated hepatic steatosis and can coexist with various hepatic and cardiovascular metabolic diseases.
Prof. Pengfei Qiu: Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?

Prof. Pengfei Qiu: Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?

The axillary lymph node burden after neoadjuvant therapy is closely related to prognosis. Unlike the assessment in initial surgery patients, residual tumor cells after neoadjuvant therapy are considered resistant cells. Thus, can limited sentinel lymph node biopsy (SLNB) metastasis after neoadjuvant therapy exempt patients from axillary lymph node dissection (ALND)? At the 2024 South-North Forum, Prof. Pengfei Qiu from Shandong Cancer Hospital presented a report titled "Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?" This article reviews the key points of his lecture.
Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure

Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure

Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with blood disorders. At this conference, a team led by Professor Yuqian Sun from Peking University People's Hospital presented their findings in an oral report titled "Salvage Haploidentical Transplantation with Flu/Cy Regimen and Donor Switching After Primary Graft Failure: Follow-Up Results," which garnered significant attention. Professor Sun was invited to share the main results of this study and the progress in salvage treatments for graft failure after haploidentical allogeneic hematopoietic stem cell transplantation.
2024 South-North Forum | Prof. Junjie Li: What’s Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?

2024 South-North Forum | Prof. Junjie Li: What’s Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?

Targeted therapy has always been a critical component of systemic treatment for HER2-positive breast cancer patients. Currently, small-molecule tyrosine kinase inhibitors (TKIs) are commonly used HER2-targeted therapies. What role do TKIs play in the neoadjuvant treatment of HER2-positive breast cancer, and what drug combinations yield the best treatment outcomes? At the 2024 South-North Forum, Prof. Junjie Li from Fudan University Cancer Hospital presented a report titled "What's Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?" This article compiles the key points from his lecture.
Professor Wenjun Zhang: Focusing on Clinical Application, Key Updates in the 2024 CSCO CAR-T Cell Therapy Guidelines | 2024 CSCO Guidelines Conference

Professor Wenjun Zhang: Focusing on Clinical Application, Key Updates in the 2024 CSCO CAR-T Cell Therapy Guidelines | 2024 CSCO Guidelines Conference

As scheduled, the 2024 China Society of Clinical Oncology (CSCO) guidelines conference has arrived, with many CSCO oncology treatment guidelines being updated or published for the first time. In the field of hematologic oncology, the much-anticipated CAR-T cell therapy guidelines have been significantly updated. The "CSCO CAR-T Cell Therapy for Malignant Hematological Diseases and Management of Related Infections Guidelines 2023" (referred to as the 2023 Guidelines) has been renamed to "CSCO CAR-T Cell Therapy for Malignant Hematological Diseases Guidelines 2024" (referred to as the 2024 Guidelines). At the conference, Professor Wenjun Zhang from Tongji Hospital affiliated with Tongji University and the Tongji University Institute of Hematology shared the key updates of the 2024 Guidelines. The highlights are organized below for our readers.

A Case of Extensive Portal Venous System Thrombosis and Prehepatic Portal Hypertension Following Transition from Low to High Altitude

To broaden the horizons and enrich the practical knowledge of clinical hepatologists, and to cultivate clinical thinking abilities, International Liver Disease has invited Professor Shanhong Tang’s team from the Department of Gastroenterology at Western Theater Command General Hospital to create the “Liver Difficult Cases” column. This column compiles "classic cases" encountered by Professor Tang’s team over years of clinical practice and treatment, and will also regularly collect complex or rare clinical cases published in renowned academic journals, emphasizing the diagnostic and therapeutic approaches for various liver diseases, providing valuable clinical references for peers.
Professor Jianming Guo : Enhancing Perioperative Predictive Performance for Kidney Cancer Patients with AI-Assisted Surgical Scoring Systems

Professor Jianming Guo : Enhancing Perioperative Predictive Performance for Kidney Cancer Patients with AI-Assisted Surgical Scoring Systems

Kidney cancer surgical scoring systems provide critical information for treatment planning, surgical method selection, tumor recurrence risk, and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from April 5 to 8, 2024, in Paris, France, where numerous studies and advancements related to kidney cancer surgery were presented. Oncology Frontier invited Professor Jianming Guo from Zhongshan Hospital, Fudan University, to share insights on preoperative and postoperative scoring systems, AI predictions of kidney tumor pathology, and prognosis.
Professor Jing Yao: Advancing Clinical Practice with Personalized Treatment Strategies for Breast Cancer Patients丨Jiangcheng Breast Cancer Academic

Professor Jing Yao: Advancing Clinical Practice with Personalized Treatment Strategies for Breast Cancer Patients丨Jiangcheng Breast Cancer Academic

In early March, as the spring begins in Jiangcheng, the cherry blossoms bloom following the plum blossoms. The 4th Jiangcheng Breast Cancer Academic Forum was successfully held in Wuhan. Experts in breast cancer surgery, medical oncology, radiotherapy, and basic and translational research gathered to present numerous research advancements and clinical development trends. After the conference, Oncology Frontier invited the conference chair, Professor Jing Yao from Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, to share highlights of the conference and developments in breast cancer diagnosis and treatment.
Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed/Refractory Multiple Myeloma: A Phase I/II Clinical Trial

Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed/Refractory Multiple Myeloma: A Phase I/II Clinical Trial

In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory multiple myeloma (R/R MM) are of paramount importance. It is in this context that the recent phase I/II, open-label study investigating the efficacy of bispecific CAR-T cell therapy targeting BCMA and CD19 comes to light, marking a significant advancement in the therapeutic domain. This study, meticulously carried out by a dedicated team of researchers led by Professor Kailin Xu from the Department of Hematology at The Affiliated Hospital of Xuzhou Medical University, alongside esteemed colleagues from various prestigious institutions across China, has been a beacon of hope for patients grappling with this relentless malignancy. The findings of this groundbreaking research were meticulously documented, underscoring not only the potential of bispecific BC19 CAR T cells as a viable treatment option but also the collaborative effort and expertise that epitomizes the spirit of innovation in the field. This endeavor, emblematic of the strides being made in hematology research, was brilliantly showcased during a session at a renowned medical conference, an event that has become a cornerstone for the dissemination of cutting-edge scientific knowledge and clinical practices.